Real-world Health Outcomes in Canadian Patients Using Semaglutide
NCT ID: NCT04175665
Last Updated: 2020-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1133 participants
OBSERVATIONAL
2020-01-06
2020-02-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To better understand the effectiveness of semaglutide on clinical outcomes in a real-world setting, this retrospective cohort study will use the Canadian LMC Diabetes Registry to examine the effects of semaglutide on glycemic control, body weight, and other clinical outcomes in patients with T2D who initiate once-weekly semaglutide as part of usual clinical care in a diabetes specialist practice group in Canada.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice
NCT04559815
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
NCT05040971
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
NCT05950516
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
NCT06161844
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
NCT05486065
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Semaglutide
Prescription for semaglutide as part of usual clinical practice
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years at medication index date
* Clinical diagnosis of type 2 diabetes for greater than six months
* ≥ one HbA1c measurement at baseline and at follow-up
* ≥ one follow-up visit post index date
* Informed consent for medical data to be used for research purposes
Exclusion Criteria
* Recent eGFR \<40 ml/min/1.73m2
* Documented history of bariatric surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LMC Diabetes & Endocrinology Ltd.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronnie Aronson, MD
Role: PRINCIPAL_INVESTIGATOR
LMC Diabetes & Endocrinology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LMC Diabetes & Endocrinology
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SPARE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.